Related Experiment Video
Updated: Jan 15, 2026
Preparation of 3D Collagen Gels and Microchannels for the Study of 3D Interactions In Vivo
Published on: May 9, 2016
Development of small molecule inhibitors of ECM collagen secretion
Ross S Mancini1, Pierre-Antoine Bissey2, Leonardo Massignan1
1Krembil Brain Institute, University Health Network Toronto Ontario Canada mark.reed@uhn.ca.
Abstract:
Tissue fibrosis is a common consequence of many different acute and chronic injuries, which severely impairs the function of affected organs. A significant challenge is the lack of effective strategies to treat fibrotic disorders. The metabolic dysregulation underlying fibrosis may be reversed by the small molecule caffeic acid phenethyl ester (CAPE), but there are limitations which prevent its clinical use. Following the identification of caffeic acid derivative 1 from an in-house library screen, we performed structure-activity relationship studies which led to the discovery of novel small molecule inhibitors of extracellular matrix (ECM) collagen secretion. The small molecules increased PPARG and CD36 expression (markers of fatty acid metabolism), suggesting a mechanism of action involving a metabolic shift from fibrotic-to-normal state. The compounds identified in this study provide a foundation for further development towards a novel, first-in-class therapeutic agent for fibrosis.
Insights
Researchers discovered novel small molecules that inhibit extracellular matrix collagen secretion, offering a potential new treatment for tissue fibrosis. These compounds may reverse metabolic dysregulation by shifting cells from a fibrotic to a normal state.
Area of Science:
- Biochemistry
- Pharmacology
- Cell Biology
Background:
- Tissue fibrosis, a result of injury, impairs organ function and lacks effective treatments.
- Metabolic dysregulation is implicated in fibrosis, with caffeic acid phenethyl ester (CAPE) showing potential but facing clinical limitations.
Purpose of the Study:
- To discover novel small molecule inhibitors of extracellular matrix (ECM) collagen secretion for treating fibrotic disorders.
- To investigate the mechanism of action of these inhibitors, focusing on metabolic pathways.
Main Methods:
- Structure-activity relationship studies were conducted on a caffeic acid derivative.
- Inhibition of ECM collagen secretion was assessed.
- Expression of PPARG and CD36, markers of fatty acid metabolism, was measured.
Main Results:
- Novel small molecule inhibitors of ECM collagen secretion were identified.
- These compounds increased the expression of PPARG and CD36.
- The findings suggest a metabolic shift from a fibrotic to a normal state.
Conclusions:
- The identified small molecules represent a promising foundation for developing first-in-class therapeutics for fibrosis.
- The mechanism involves modulating fatty acid metabolism to counteract fibrotic processes.
More Related Videos
07:03Imaging Denatured Collagen Strands In vivo and Ex vivo via Photo-triggered Hybridization of Caged Collagen Mimetic Peptides
Published on: January 31, 2014
10:45Organotypic Collagen I Assay: A Malleable Platform to Assess Cell Behaviour in a 3-Dimensional Context
Published on: October 13, 2011
Related Concept Videos
01:23Role of Matrix Metalloproteases in Degradation of ECM
01:13Collagens are the Major Structural Proteins of ECM
Connective tissue proper includes loose...
01:42The Extracellular Matrix
01:56Structural Protein Function
Collagen, the most abundant protein in mammals, is found throughout the body. In connective tissue, such as skin, ligaments, and tendons, it provides tensile strength and elasticity. In bones and teeth, it mineralizes to...